182 related articles for article (PubMed ID: 32737841)
1. Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?
Sanchis-Gomar F; Lavie CJ; Morin DP; Perez-Quilis C; Laukkanen JA; Perez MV
Am J Cardiovasc Drugs; 2020 Oct; 20(5):413-418. PubMed ID: 32737841
[TBL] [Abstract][Full Text] [Related]
2. Direct SARS-CoV-2 infection of the heart potentiates the cardiovascular sequelae of COVID-19.
Bose RJC; McCarthy JR
Drug Discov Today; 2020 Sep; 25(9):1559-1560. PubMed ID: 32592868
[No Abstract] [Full Text] [Related]
3. Recombinant human ACE2: potential therapeutics of SARS-CoV-2 infection and its complication.
Pang X; Cui Y; Zhu Y
Acta Pharmacol Sin; 2020 Sep; 41(9):1255-1257. PubMed ID: 32581256
[No Abstract] [Full Text] [Related]
4. Does Ibuprofen Worsen COVID-19?
Moore N; Carleton B; Blin P; Bosco-Levy P; Droz C
Drug Saf; 2020 Jul; 43(7):611-614. PubMed ID: 32529474
[No Abstract] [Full Text] [Related]
5. Can beta-adrenergic blockers be used in the treatment of COVID-19?
Vasanthakumar N
Med Hypotheses; 2020 Sep; 142():109809. PubMed ID: 32388480
[No Abstract] [Full Text] [Related]
6. Could a specific ACE2 activator drug improve the clinical outcome of SARS-CoV-2? A potential pharmacological insight.
Nicolau LAD; NolĂȘto IRSG; Medeiros JVR
Expert Rev Clin Pharmacol; 2020 Aug; 13(8):807-811. PubMed ID: 32686527
[No Abstract] [Full Text] [Related]
7. The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system.
Offringa A; Montijn R; Singh S; Paul M; Pinto YM; Pinto-Sietsma SJ
Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):317-325. PubMed ID: 32464637
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management.
Wu L; O'Kane AM; Peng H; Bi Y; Motriuk-Smith D; Ren J
Biochem Pharmacol; 2020 Aug; 178():114114. PubMed ID: 32579957
[TBL] [Abstract][Full Text] [Related]
9. H
Yang G
Am J Physiol Cell Physiol; 2020 Aug; 319(2):C244-C249. PubMed ID: 32515982
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19).
Bourgonje AR; Abdulle AE; Timens W; Hillebrands JL; Navis GJ; Gordijn SJ; Bolling MC; Dijkstra G; Voors AA; Osterhaus AD; van der Voort PH; Mulder DJ; van Goor H
J Pathol; 2020 Jul; 251(3):228-248. PubMed ID: 32418199
[TBL] [Abstract][Full Text] [Related]
11. Are there any Therapeutic Options Currently Available for Wuhan Coronavirus?
Carradori S
Antiinflamm Antiallergy Agents Med Chem; 2020; 19(2):85-87. PubMed ID: 32213152
[No Abstract] [Full Text] [Related]
12. Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting.
Sharifkashani S; Bafrani MA; Khaboushan AS; Pirzadeh M; Kheirandish A; Yavarpour Bali H; Hessami A; Saghazadeh A; Rezaei N
Eur J Pharmacol; 2020 Oct; 884():173455. PubMed ID: 32745604
[TBL] [Abstract][Full Text] [Related]
13. Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19.
Poduri R; Joshi G; Jagadeesh G
Cell Signal; 2020 Oct; 74():109721. PubMed ID: 32711111
[TBL] [Abstract][Full Text] [Related]
14. Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic.
South AM; Tomlinson L; Edmonston D; Hiremath S; Sparks MA
Nat Rev Nephrol; 2020 Jun; 16(6):305-307. PubMed ID: 32246101
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 and Kidney Disease: Molecular Determinants and Clinical Implications in Renal Cancer.
Mihalopoulos M; Dogra N; Mohamed N; Badani K; Kyprianou N
Eur Urol Focus; 2020 Sep; 6(5):1086-1096. PubMed ID: 32540268
[TBL] [Abstract][Full Text] [Related]
16. The mechanism and treatment of gastrointestinal symptoms in patients with COVID-19.
Ye Q; Wang B; Zhang T; Xu J; Shang S
Am J Physiol Gastrointest Liver Physiol; 2020 Aug; 319(2):G245-G252. PubMed ID: 32639848
[TBL] [Abstract][Full Text] [Related]
17. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA
Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122
[TBL] [Abstract][Full Text] [Related]
18. Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS).
Cadegiani FA; Goren A; Wambier CG
Med Hypotheses; 2020 Oct; 143():110112. PubMed ID: 32721806
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?
Sargiacomo C; Sotgia F; Lisanti MP
Aging (Albany NY); 2020 Mar; 12(8):6511-6517. PubMed ID: 32229706
[TBL] [Abstract][Full Text] [Related]
20. Management of Atrial Fibrillation in COVID-19 Pandemic.
Hu YF; Cheng WH; Hung Y; Lin WY; Chao TF; Liao JN; Lin YJ; Lin WS; Chen YJ; Chen SA
Circ J; 2020 Sep; 84(10):1679-1685. PubMed ID: 32908073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]